These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 34421548)

  • 1. The Cerebellar Dopaminergic System.
    Flace P; Livrea P; Basile GA; Galletta D; Bizzoca A; Gennarini G; Bertino S; Branca JJV; Gulisano M; Bianconi S; Bramanti A; Anastasi G
    Front Syst Neurosci; 2021; 15():650614. PubMed ID: 34421548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine and the regulation of cognition and attention.
    Nieoullon A
    Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic regulation of vestibulo-cerebellar circuits through unipolar brush cells.
    Canton-Josh JE; Qin J; Salvo J; Kozorovitskiy Y
    Elife; 2022 Apr; 11():. PubMed ID: 35476632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.
    Kishore A; Popa T
    Front Neurol; 2014; 5():157. PubMed ID: 25183959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connecting the dots of the cerebro-cerebellar role in cognitive function: neuronal pathways for cerebellar modulation of dopamine release in the prefrontal cortex.
    Rogers TD; Dickson PE; Heck DH; Goldowitz D; Mittleman G; Blaha CD
    Synapse; 2011 Nov; 65(11):1204-12. PubMed ID: 21638338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
    Hurley MJ; Mash DC; Jenner P
    Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases.
    Sundararajan T; Manzardo AM; Butler MG
    Gene; 2018 Jan; 641():25-34. PubMed ID: 29032150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reorganization of circuits underlying cerebellar modulation of prefrontal cortical dopamine in mouse models of autism spectrum disorder.
    Rogers TD; Dickson PE; McKimm E; Heck DH; Goldowitz D; Blaha CD; Mittleman G
    Cerebellum; 2013 Aug; 12(4):547-56. PubMed ID: 23436049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.
    Gilat M; Bell PT; Ehgoetz Martens KA; Georgiades MJ; Hall JM; Walton CC; Lewis SJG; Shine JM
    Neuroimage; 2017 May; 152():207-220. PubMed ID: 28263926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
    Jones-Tabah J
    J Mol Biol; 2023 Jun; 435(12):167927. PubMed ID: 36563742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine receptor D2 on CD4
    Liu Z; Zhai XR; Du ZS; Xu FF; Huang Y; Wang XQ; Qiu YH; Peng YP
    Brain Behav Immun; 2021 Nov; 98():110-121. PubMed ID: 34403737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus.
    Dirkx MF; den Ouden HE; Aarts E; Timmer MH; Bloem BR; Toni I; Helmich RC
    Brain; 2017 Mar; 140(3):721-734. PubMed ID: 28073788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia.
    Rodríguez De Fonseca F; Gorriti MA; Bilbao A; Escuredo L; García-Segura LM; Piomelli D; Navarro M
    Neurotox Res; 2001 Jan; 3(1):23-35. PubMed ID: 15111259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA.
    Nandhu MS; Paul J; Kuruvila KP; Abraham PM; Antony S; Paulose CS
    Mol Cell Biochem; 2011 Jul; 353(1-2):47-57. PubMed ID: 21384157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.